Executive Team
Dr. Frederick S. Hagen is founder, President, and CEO of Icogenex. During his tenure at ZymoGenetics, from 1982 to 1994, Dr. Hagen served in a number of leadership roles. Major accomplishments include cloning and expression of the cDNA for Factor VII. This blood coagulation protein is currently a $1 billion a year product for Novo Nordisk. Another discovery was the identification of cDNA encoding Thrombopoietin, the growth factor regulator of platelet production that was licensed to Amgen.
In 13 years with ZymoGenetics, Dr. Hagen experienced first-hand the development and maturation of a biotechnology company from startup through buyout by Novo Nordisk. While at ZymoGenetics, he also worked for a year at Novo Nordisk headquarters in Copenhagen, Denmark, where he gained experience in the operations of a large pharmaceutical company.
Dr. Hagen has 21 issued patents and is an author on 34 peer reviewed journal articles. Dr Hagen received his Ph.D. from the University of Washington and completed his postdoctoral work at Harvard Medical School.
Jerry McGuire, CFO of Icogenex, has over 20 years of experience in guiding the financial affairs of technology companies. For the last 11 years he has worked as a consulting CFO for over twenty early stage biotechnology and software companies. During this time, he advised such companies as Darwin Molecular, Aeiveos, CEPTYR, Inc., Activate.net, Chronology Corp. and Captura.
Previously, he held executive positions with SeaMED Corporation and Source Technologies and was a consultant with Deloitte Haskins and Sells. He is a Certified Public Accountant and holds an MBA in finance from the University of Southern California.
Board of Directors
Dr. Frederick S. Hagen, President and CEO of Icogenex (bio)
James B. Glavin has 38 years of experience in the health care pharmaceutical industry. He has been Chairman of the Board of Directors of Immune Response since May 1993, CEO from April 1987 to September 1994, President from October 1987 to September 1994, and Treasurer from April 1987 to May 1991. He was Chairman of the Board of Directors of Smith Laboratories, Inc., a medical products company, from September 1985 to May 1990 and Acting President and CEO from September 1985 to August 1989.
During 1985 to 1987 Mr. Glavin was a Partner in CH Ventures. From 1981 to 1983, he was President and CEO of Genetics Systems Corporation and Chairman of the Board from 1983 to 1985. In addition to being Director and Chairman of Immune Response, he is currently a Director of Nektar Therapeutic Systems, Inc., formerly Inhale Therapeutic Systems, Inc., Meridian Fund, and Chairman of the Board of Avanir Pharmaceuticals.
Scientific Advisors
Dr. Niels H. Andersen is a Professor in the Department of Chemistry at the University of Washington. His work focuses on the fundamental thermodynamics and structural features associated with biorecognition and practical applications of drug design. He has developed a substantial body of work around structural identification of bioactive compounds isolated from natural sources and, more recently, synthesis and design of drug candidates based on SAR in a lead series and NMR structure based design. Dr. Andersen is an expert at using multi-dimensional proton, carbon and fluorine NMR for structure and stereochemistry determination, and the use of circular dichroism to determine absolute stereochemistry.
Dr. Julian A. Simon is an Assistant Professor at the Fred Hutchinson Cancer Research Center, where he is an expert in anti-cancer drug screening. A chemist by training, Dr. Simon has developed a research program around drug screening involving both synthetic chemistry and genetic screening. He has strong interest and breadth of knowledge in natural products as sources for anti-cancer drug development as well as extensive knowledge of classes of chemical compounds that can potentially be useful for drug development. He is very knowledgeable about of extraction processes of natural product sources as well as the development of relevant biological paradigms in which to test molecules from natural product sources.
Dr. George M. Martin is an active Emeritus Professor of Pathology at the University of Washington and former long time director of the University of Washington Alzheimer's Disease Research Center. As such, his career spans the modern investigation of Alzheimer's disease. His knowledge and contacts in the field are invaluable. His current research interests lie in the application of genetic concepts and methodologies to the elucidation of the pathobiology of aging in man, other mammals, and birds. These studies also address genetic mechanisms underlying the unusual resistance of certain avian species to oxidative damage.
Outside Counsel
Orrrick, Herrington, & Sutcliffe LLP is Icogenex's outside general counsel. Overseeing the account is Roger M. Tolbert, a member of the firm's Corporate Department, the leader of the intellectual property contracting and licensing practice in Orrick's Seattle office. He assists clients in diverse industries with a wide range of intellectual property, contracting, and alliance matters.
Before joining Orrick, Mr. Tolbert was a partner with Perkins Coie LLP, where he co-chaired the life sciences practice group. He is a frequent speaker and program chair at educational programs that focus on protection and exploitation of intellectual properties. He received his J.D. from Yale Law School.